Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Management of dyspnea at the end of life

Michael P. Slawnych
CMAJ May 19, 2020 192 (20) E550; DOI: https://doi.org/10.1503/cmaj.200488
Michael P. Slawnych
Division of Palliative Care and Libin Cardiovascular Institute, University of Calgary, Calgary, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

No one should die suffering from breathlessness

All physicians should be prepared to manage dyspnea, especially during the coronavirus disease 2019 pandemic.1 Dyspnea, a subjective experience of uncomfortable breathlessness, can usually be well managed using subcutaneous medications, with a butterfly infusion set being a good access option because it prevents the need for repeated needle injections and can remain in place for days.2

Opioids are the mainstay for managing dyspnea at the end of life

It is suggested that physicians start with opioids,3 which do not impair respiratory status or hasten death when used appropriately with a symptom focus (e.g., hydromorphone 0.5 mg subcutaneously every 4 h, and 0.5 mg subcutaneously every 30 min, as needed).4 The dosage should be reassessed frequently. Physicians should be prepared to escalate the dose rapidly if necessary. Subcutaneous opioids are twice as powerful as oral opioids (e.g., hydromorphone 1.0 mg taken orally has about the same effect as 0.5 mg administered subcutaneously).

If dyspnea persists, a benzodiazepine may be added

Benzodiazepines can be helpful, particularly if the patient has associated anxiety (e.g., lorazepam 0.5 mg subcutaneously every 2 h, as needed [the dose can be increased if necessary]). For ongoing refractory dyspnea, palliative sedation may be required. A palliative physician should be involved if progressing to this treatment.

Patients often develop bothersome secretions owing to swallowing difficulties

There is usually no role for suctioning, which is often uncomfortable for patients. Anticholinergics are the medication of choice to reduce secretions. Clinicians may choose between scopolamine and glycopyrrolate depending on whether sedation is preferred (e.g., scopolamine 0.4 mg subcutaneously every 4 h as needed [sedating]; glycopyrrolate 0.4 mg subcutaneously every 4 h as needed [not sedating]). Mouth swabs can be helpful for mouth dryness.

Patients’ dyspnea-related agitation can distress their loved ones

Using an antipsychotic is suggested for managing agitation. Methotrimeprazine is favoured because of its sedative properties (e.g., methotrimeprazine 6.25 mg subcutaneously every 6 h as needed [the dose can be increased if needed]). A benzodiazepine is also sometimes added, particularly near the end of life.

CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj

Footnotes

  • CMAJ Podcasts: author interview at https://soundcloud.com/cmajpodcasts/200488-five

  • Competing interests: Michael Slawnych reports receiving a speaker fee as a member of a speaker bureau, Novartis.

  • This article has been peer reviewed.

References

  1. ↵
    1. Arya A,
    2. Buchman S,
    3. Gagnon B,
    4. et al
    . Pandemic palliative care: beyond ventilators and saving lives. CMAJ 2020;192: E400–4.
    OpenUrlFREE Full Text
  2. ↵
    1. Goldstein NE,
    2. Morrison RS
    . Evidence-based practice of palliative medicine. Philadelphia: Elsevier Saunders; 2013.
  3. ↵
    1. Currow DC,
    2. Ward AM,
    3. Abernethy AP
    . Advances in the pharmacological management of breathlessness. Curr Opin Support Palliat Care 2009;3:103–6.
    OpenUrlPubMed
  4. ↵
    1. Gallagher R
    . Killing the symptom without killing the patient. Can Fam Physician 2010;56:544–6, e210–2.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 192 (20)
CMAJ
Vol. 192, Issue 20
19 May 2020
  • Table of Contents
  • Index by author

Article extras

  • Podcast

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Management of dyspnea at the end of life
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Management of dyspnea at the end of life
Michael P. Slawnych
CMAJ May 2020, 192 (20) E550; DOI: 10.1503/cmaj.200488

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Management of dyspnea at the end of life
Michael P. Slawnych
CMAJ May 2020, 192 (20) E550; DOI: 10.1503/cmaj.200488
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • No one should die suffering from breathlessness
    • Opioids are the mainstay for managing dyspnea at the end of life
    • If dyspnea persists, a benzodiazepine may be added
    • Patients often develop bothersome secretions owing to swallowing difficulties
    • Patients’ dyspnea-related agitation can distress their loved ones
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Prise en charge de la dyspnée en fin de vie
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Management of γ-hydroxybutyrate intoxication and withdrawal
  • Tuberculous monoarthritis of the knee joint
  • Vulvar condyloma lata as a first presentation of syphilis
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Drugs: pain (including opioids)
    • Family medicine, general practice, primary care
    • Infectious diseases: COVID-19
    • Palliative medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire